Beta Drugs Limited — Results, 25-01-2025: Integrated Filing- Governance

Beta Drugs Ltd. has submitted its Quarterly Integrated Filing (Governance) Report for the quarter ending December 31, 2024. Notably, the company received no investor complaints, maintaining a clean track record in this regard. However, it did incur a fine of ₹10,000 plus GST due to a one-day delay in filing the XBRL for AGM voting results, with no significant operational impact reported. As a company listed on the SME platform, it is not subject to certain corporate governance reporting requirements, suggesting a continued focus on operational efficiency. This filing may foster a positive outlook among investors, reflecting the company’s commitment to compliance and effective governance practices.